Last update :
28/04/2024
Anticancer drug   Trastuzumab  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Herceptin Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Ecuador, Egypt, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Iran, Ireland, Italy, Japan, Luxembourg, Malaysia, Mexico, Morocco, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Saudi Arabia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United States of America
Herclon Peru
Hertraz Chile
Herzuma Belgium, France, Germany, Great Britain, Spain, United States of America
Kanjinti Belgium, Germany, Great Britain, Spain
Trastuzumab Baxter New Zealand
Trazimera Great Britain
Stability of mixtures   Injection   Stability of mixtures : Trastuzumab     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Polyvinyl chloride Sodium chloride 0,9% 2.3 mg/ml
Injection   Trastuzumab   
Injection   Pertuzumab 2.7 mg/ml
30°C
24 Hour
Light 3366
Level of evidence B+
Polyvinyl chloride Sodium chloride 0,9% 2.3 mg/ml
Injection   Trastuzumab   
Injection   Pertuzumab 2.7 mg/ml
5°C
24 Hour
Not specified 3366
Level of evidence B+
Polyolefine Sodium chloride 0,9% 1.5 mg/ml
Injection   Trastuzumab   
Injection   Pertuzumab 1.5 mg/ml
30°C
24 Hour
Protect from light 3366
Level of evidence B+
Polyolefine Sodium chloride 0,9% 2.3 mg/ml
Injection   Trastuzumab   
Injection   Pertuzumab 2.7 mg/ml
30°C
24 Hour
Light 3366
Level of evidence B+
Polyolefine Sodium chloride 0,9% 2.3 mg/ml
Injection   Trastuzumab   
Injection   Pertuzumab 2.7 mg/ml
5°C
24 Hour
Not specified 3366
Level of evidence B+

  Mentions Légales